14Indexed trials
mesh condition
Carcinoma, Non-Small-Cell Lung
Intelligence
Carcinoma, Non-Small-Cell Lung intelligence: 14 indexed trials, 3 recruiting studies, 8 sponsors across 40 countries.
3Recruiting
8Sponsors
40Countries
Leading sponsors
Merck Sharp & Dohme LLC63 recruiting
Incyte Corporation20 recruiting
Lisa Sanderson Cox, PhD10 recruiting
McGill University10 recruiting
NovoCure GmbH10 recruiting
Ankara Etlik City Hospital10 recruiting
Universitätsmedizin Mannheim10 recruiting
Chinese Academy of Medical Sciences10 recruiting
Geographic activity
United States9trials
Spain6trials
Italy5trials
Germany5trials
Israel5trials
Poland5trials
Canada4trials
Hungary4trials
Taiwan3trials
South Korea3trials
China3trials
France3trials
Leading interventions
Pembrolizumab4trials
Docetaxel2trials
Pemetrexed2trials
Epacadostat2trials
Carboplatin2trials
Cisplatin2trials
Gemcitabine1trials
Best Standard of Care1trials
Docetetaxel1trials
Camrelizumab, PD-1 monoclonal antibody1trials
Corticosteroid1trials
Blood Sample Collection1trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.